Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Synergistic antitumor effects and mechanisms of KPT-330 combined with venetoclax in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

WDWeidong Ding

Discussion

Loading...

Member takes

Overview

Combination therapy improves apoptosis and reduces IC50 in acute myeloid leukemia, indicating potential against resistance.

Key Points

  • Combination therapy reduced IC50 from 50 nM to 18 nM for venetoclax in MOLM-13 cells, enhancing anti-tumor efficacy.
  • MCL1 suppression and NOXA upregulation were essential for activation of apoptosis pathways in AML models.
  • Using in vivo imaging system, the therapy reduced tumor burden significantly in patient-derived xenograft models.
  • Findings suggest a promising strategy to overcome venetoclax resistance and improve outcomes in acute myeloid leukemia.

Cite This Study

Weidong Ding (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfa3https://doi.org/10.1182/blood-2025-6104
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TP53 activation by the natural quassinoid brusatol enhances venetoclax efficacy and overcomes resistance in myeloid leukemias2025
  2. 2Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia2025
  3. 3LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring2025
  4. 4Inhibition of CDK 9 enhances AML cell death induced by combined venetoclax and azacitidine2025 · 1 citations
  5. 5Factors affecting response and resistance to venetoclax in acute myeloid leukemia2025 · 6 citations